Scarica l'app Stockscreener
28.00
0.72%
0.20
Dopo l'orario di chiusura:
27.79
-0.21
-0.75%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ARWR Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$27.80
Aprire:
$28
Volume 24 ore:
3.36M
Relative Volume:
1.62
Capitalizzazione di mercato:
$3.87B
Reddito:
$181.74M
Utile/perdita netta:
$-143.97M
Rapporto P/E:
-20.14
EPS:
-1.39
Flusso di cassa netto:
$9.60M
1 W Prestazione:
+25.34%
1M Prestazione:
+70.06%
6M Prestazione:
+63.65%
1 anno Prestazione:
+16.76%
Intervallo 1D:
$27.28
$29.34
Intervallo di 1 settimana:
$21.61
$29.34
Portata 52W:
$9.57
$29.34
Arrowhead Pharmaceuticals Inc Stock (ARWR) Company Profile
Nome
Arrowhead Pharmaceuticals Inc
Settore
Industria
Telefono
626-696-4702
Indirizzo
177 E COLORADO BLVD, PASADENA, CA
Confronta ARWR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ARWR
Arrowhead Pharmaceuticals Inc
|
28.00 | 3.55B | 181.74M | -143.97M | 9.60M | -1.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Arrowhead Pharmaceuticals Inc Stock (ARWR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-06-05 | Iniziato | Goldman | Neutral |
| 2023-12-04 | Iniziato | BofA Securities | Buy |
| 2023-09-19 | Iniziato | Citigroup | Neutral |
| 2023-07-21 | Iniziato | TD Cowen | Outperform |
| 2023-05-12 | Downgrade | SVB Securities | Outperform → Market Perform |
| 2023-04-26 | Iniziato | SMBC Nikko | Outperform |
| 2023-04-12 | Aggiornamento | SVB Securities | Market Perform → Outperform |
| 2023-03-21 | Iniziato | Bernstein | Mkt Perform |
| 2022-09-09 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-05-11 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2022-01-19 | Ripresa | Goldman | Buy |
| 2021-08-06 | Reiterato | Chardan Capital Markets | Buy |
| 2021-06-04 | Ripresa | Robert W. Baird | Neutral |
| 2021-02-05 | Reiterato | H.C. Wainwright | Buy |
| 2020-12-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-12-16 | Iniziato | UBS | Buy |
| 2020-11-19 | Iniziato | Citigroup | Buy |
| 2020-05-13 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-05-08 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2020-04-15 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2020-03-24 | Aggiornamento | SVB Leerink | Underperform → Mkt Perform |
| 2020-03-17 | Iniziato | Goldman | Neutral |
| 2020-01-21 | Iniziato | SVB Leerink | Underperform |
| 2019-12-13 | Iniziato | Oppenheimer | Perform |
| 2019-11-29 | Reiterato | Chardan Capital Markets | Buy |
| 2019-11-27 | Reiterato | B. Riley FBR | Buy |
| 2019-11-25 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2019-10-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2019-10-22 | Reiterato | Chardan Capital Markets | Buy |
| 2019-10-03 | Iniziato | Robert W. Baird | Outperform |
| 2018-09-07 | Aggiornamento | B. Riley FBR | Neutral → Buy |
| 2018-09-06 | Reiterato | Chardan Capital Markets | Buy |
| 2018-08-08 | Reiterato | Cantor Fitzgerald | Overweight |
| 2018-07-02 | Reiterato | Chardan Capital Markets | Buy |
Mostra tutto
Arrowhead Pharmaceuticals Inc Borsa (ARWR) Ultime notizie
Arrowhead Lands Billion-Dollar Biotech Deal: Stock Soars Double-Digits - Yahoo Finance
Transcript : Arrowhead Pharmaceuticals, Inc. Presents at Citi's Biopharma Back to School Conference, Sep-03-2025 01 - MarketScreener
Arrowhead Pharmaceuticals and Novartis sign global deal for siRNA therapy - MSN
Arrowhead: Upcoming Plozasiran PDUFA Review Date And Subsequent Expansion In Place (ARWR) - Seeking Alpha
Will Arrowhead Pharmaceuticals Inc. benefit from AI trendsJuly 2025 Update & AI Powered Buy and Sell Recommendations - khodrobank.com
Identifying reversal signals in Arrowhead Pharmaceuticals Inc.Earnings Recap Report & Daily Oversold Stock Bounce Ideas - Newser
Arrowhead Pharmaceuticals stock hits 52-week high at 27.35 USD - Investing.com
Will earnings trigger a reversal in Arrowhead Pharmaceuticals Inc.Dividend Hike & Momentum Based Trading Ideas - Newser
Arrowhead and Novartis sign agreement for ARO-SNCA - BioWorld MedTech
Arrowhead Pharmaceuticals Inc.’s volatility index tracking explainedPortfolio Profit Report & AI Forecast for Swing Trade Picks - Newser
Can a trend reversal in Arrowhead Pharmaceuticals Inc. lead to recoveryEntry Point & Smart Investment Allocation Insights - Newser
Is Arrowhead Pharmaceuticals Inc. stock entering bullish territory2025 Short Interest & Fast Gaining Stock Reports - Newser
Arrowhead Pharmaceuticals Inc. stock momentum explained2025 Performance Recap & Technical Entry and Exit Alerts - Newser
Using data models to predict Arrowhead Pharmaceuticals Inc. stock movement2025 Technical Patterns & Risk Controlled Swing Alerts - Newser
Detecting price anomalies in Arrowhead Pharmaceuticals Inc. with AI2025 Fundamental Recap & High Accuracy Swing Trade Signals - Newser
Arrowhead Pharmaceuticals shares fall 1.40% premarket after announcing a global licensing and collaboration agreement with Novartis for ARO-SNCA. - AInvest
Using Ichimoku Cloud for Arrowhead Pharmaceuticals Inc. technicalsPortfolio Return Summary & Low Drawdown Momentum Ideas - Newser
Arrowhead Pharmaceuticals Inc. stock volume spike explainedJuly 2025 Retail & Daily Chart Pattern Signals - Newser
Arrowhead hits the skids due to partnership with Sarepta - MSN
Arrowhead Pharmaceuticals Inc. stock trendline breakdownJuly 2025 Short Interest & Low Risk High Win Rate Picks - Newser
Analyzing net buyer seller activity in Arrowhead Pharmaceuticals Inc.Quarterly Trade Summary & Community Consensus Trade Alerts - Newser
Stocks To Watch: Arrowhead Pharm Sees RS Rating Jump To 89 - Investor's Business Daily
Will breakout in Arrowhead Pharmaceuticals Inc. lead to full recovery2025 Support & Resistance & Long-Term Safe Return Strategies - Newser
Published on: 2025-09-03 01:49:11 - Newser
Using Python tools to backtest Arrowhead Pharmaceuticals Inc. strategies2025 Analyst Calls & Real-Time Buy Zone Alerts - Newser
Arrowhead Pharmaceuticals (ARWR) Soars 16.57% on $2B Novartis Deal Validating TRiM Platform - AInvest
How to forecast Arrowhead Pharmaceuticals Inc. trends using time seriesPortfolio Return Report & High Yield Equity Trading Tips - Newser
Will Arrowhead Pharmaceuticals Inc. price bounce be sustainableJuly 2025 Market Mood & Weekly Breakout Stock Alerts - Newser
How to use Fibonacci retracement on Arrowhead Pharmaceuticals Inc.2025 Performance Recap & Technical Pattern Alert System - Newser
Published on: 2025-09-02 22:39:01 - Newser
Sarepta Sells Arrowhead Stake To Stretch Its Cash Runway; And One Stock Dives - MSN
Does Arrowhead Pharmaceuticals Inc. have strong fundamentalsJuly 2025 Summary & Weekly Top Gainers Alerts - khodrobank.com
Arrowhead, Novartis Partner In Neuroscience, An Active Deal Area For Both - insights.citeline.com
Arrowhead, Novartis in up to $2 billion deal for neuromuscular therapy license - Reuters
Arrowhead Pharma Jumps After Inking A Deal Worth Up To $2.2 Billion - Investor's Business Daily
Arrowhead Pharmaceuticals inks $200 million deal with Novartis for Parkinson's disease treatment - AInvest
Arrowhead jumps on news of $2B deal with Novartis - The Pharma Letter
Applying chart zones and confluence areas to Arrowhead Pharmaceuticals Inc.Gold Moves & Precise Entry and Exit Recommendations - Newser
Arrowhead Pharmaceuticals stock surges on $200 million Novartis deal - Investing.com
Ionis reports sHTG win while Arrowhead inks Novartis deal - BioWorld MedTech
Arrowhead piques Novartis’ neuro interest with $200M upfront deal - Endpoints News
Air Lease, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday - Benzinga
Arrowhead Pharmaceuticals, Novartis Ink $2.2 Billion Deal for Parkinson’s Therapy and RNAi Platform - Contract Pharma
Arrowhead Stock Rockets 11% Today – Retail Says $200M Upfront Payment From Novartis Collaboration Is ‘Hell Of A Deal’ - Stocktwits
Arrowhead Nabs up to $2B Novartis Commitment for siRNA Parkinson’s Program - BioSpace
Arrowhead Pharmaceuticals and Novartis Partner for Parkinson's Disease Treatment, Valued at Up to $2.2 Billion - AInvest
Arrowhead and Novartis agree up to $2 billion deal for license to neuromuscular therapy - Reuters
Arrowhead Pharmaceuticals Eligible for Up to $2 Billion in Potential Milestone Payments Under New Novartis Deal - MarketScreener
Arrowhead Pharmaceuticals and Novartis Enter into a Global License and Collaboration Agreement - Business Wire
Arrowhead Pharmaceuticals Inc Azioni (ARWR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Arrowhead Pharmaceuticals Inc Azioni (ARWR) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Hamilton James C | Chief Medical Officer |
Aug 15 '25 |
Sale |
20.00 |
9,389 |
187,780 |
262,122 |
| Hamilton James C | Chief Medical Officer |
Aug 13 '25 |
Sale |
20.00 |
611 |
12,220 |
271,511 |
1.75%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):